GENFERON® - is a combined drug the composition of which includes recombinant human interferon alpha-2b, benzocaine and taurine. Genferon is used as a part of complex therapy for infectious and inflammatory diseases of the urogenital tract in adults: mycoplasma, ureaplasma, chlamydia, genital herpes, vaginal candida, chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, Behçet's disease, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, mastocytosis and malignant melanoma.
- COVID-19 (not approved, currently used in clinical trials in US, China, Australia and Canada)
- Wide range of indications, including viral, bacterial infections and cancers.
- Acute bronchitis in adults.
- Chronic recurrent cystitis of bacterial etiology in adults.
- Chronic endometritis in adults.
GUARANTEE & EXPIRY DATE
100% original from Russian pharmaceutical company Biocad. All packs are air tight sealed and expire up to 01.2026. Photos of the product are for illustation purpose only and may vary according to the manufacturer.
Interferon alfa-2b has an antiviral, immunomodulatory, antiproliferative and antibacterial effect.
The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit virus replication. The immunomodulatory effect is manifested, first of all, by the enhancement of cell-mediated reactions of the immune system, which increases the efficiency of the immune response against viruses, intracellular parasites and cells that underwent tumor transformation.
This is achieved through the activation of CD8 + T-killers, NK cells (natural killers), increased differentiation of B-lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the main histocompatibility complex of type I, which increases the likelihood recognition of infected cells by cells of the immune system.
Activation of leukocytes contained in all layers of the mucous membrane under the influence of interferon ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, the production of secretory immunoglobulin A is restored. The antibacterial effect is mediated by reactions of the immune system enhanced by the influence of interferon.
Taurine contributes to the normalization of metabolic processes and tissue regeneration, has a membrane-stabilizing and immunomodulating effect. Being a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes.
Taurine helps preserve the biological activity of interferon, enhancing the therapeutic effect of the drug.
GENFERON® comes in the following forms:
Intranasal spray - 50 000 IU + 1 mg (taurine) per dose, 100 doses per flacon
Rectal/vaginal suppositories - 250 000 IU (interferon alfa-2b) + 5 mg (taurine) per suppository, 10 suppositories per pack
Rectal/vaginal suppositories - 500 000 IU (interferon alfa-2b) + 10 mg (taurine) + 55 mg (benzocaine) per suppository, 10 suppositories per pack
Rectal/vaginal suppositories - 1 000 000 IU (interferon alfa-2b) + 10 mg (taurine) + 55 mg (benzocaine) per suppository, 10 suppositories per pack
The drug is administered intranasally by aerosol administration of 1 dose (1 dose = 1 short press on the dispenser).
At the first signs of the disease, Genferon® Light spray is administered intranasally for 5 days at a single dose (one press on the dispenser) in each nasal passage 3 times a day (one dose is approximately 50 000 IU of interferon alfa, daily should not exceed 500 000 IU). In contact with a patient with acute respiratory viral infections and / or with hypothermia, the drug is administered according to the specified scheme 2 times a day for 5-7 days. If necessary, preventive courses are repeated.
1. Infectious and inflammatory diseases of the urogenital tract in women.
One suppository (250 000 IU or 500 000 IU or 1 000 000 IU, depending on the severity of the disease) vaginally or rectally (depending on the nature of the disease) 2 times a day daily for 10 days. With protracted forms 3 times a week every other day, 1 suppository for 1-3 months.
With a pronounced infectious and inflammatory process in the vagina, it is possible to use 1 suppository 500 000 IU intravaginally in the morning and 1 suppository 1 000 000 IU rectally at night, simultaneously with the introduction of a suppository containing antibacterial / fungicidal agents into the vagina.
To normalize the indices of local immunity in the treatment of infectious and inflammatory diseases of the urogenital tract in women with a gestational age of 13-40 weeks, 1 suppository of 250 000 IU is used vaginally 2 times a day daily for 10 days.
2. Infectious and inflammatory diseases of the urogenital tract in men.
Rectally, 1 suppository (500 000 IU or 1 000 000 IU, depending on the severity of the disease) 2 times a day for 10 days.
3. As part of the complex treatment of acute bronchitis in adults.
One suppository (1 000 000 IU) rectally 2 times a day for 5 days.
4. As part of the complex therapy of chronic recurrent cystitis in adults.
In case of exacerbation - 1 suppository (1 000 000 IU) rectally 2 times a day for 10 days in combination with a standard course of antibacterial therapy, then 1 suppository (1 000 000 IU) rectally every other day for 40 days in order to prevent relapse .
5. As part of the complex therapy of chronic endometritis in adults.
Rectally, 1 suppository (1 000 000 IU) 2 times a day for 10 days, then 1 suppository (500 000 IU) rectally 2 times a day for 10 days, then rectally 1 suppository (1 000 000 IU) through day for 10 days.
- To prevent urogenital reinfection, it is recommended to consider the simultaneous treatment of a sexual partner.
- The use of the drug during menstruation is allowed.
- GENFERON® does not affect the execution of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.).
- Dot use for children younger than 5 years old.
The drug is well tolerated by patients.
Very rare adverse reactions (<1/10000):
General disorders and disorders at the injection site.
Allergic reactions are possible, including local ones. Continuation of treatment is possible after consultation with a doctor.
Phenomena may occur that occur with all types of interferon alfa-2b, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, and leukemia and thrombocytopenia, but they are more common when exceeded daily dose over.
10 000 000 IU. To date, no serious adverse events have been observed.
As with any other preparation of interferon alfa-2b, in case of temperature increase after its administration, a single dose of paracetamol in a dose is possible
The drug is stored in a dark place at a temperature of 2-10 degrees Celcius.
Ask us any questions about GENFERON.